Cabergoline CAS 81409-90-7 Raw Materials Powder

CAS: 81409-90-7

MF:  C26H37N5O2

MW:  451.6

EINECS: 200-419-0

Specification​: 99% min Cabergoline 

Sample: Cabergoline Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Portal:https://henrikang.en.made-in-china.com/

Cabergoline Powder Usage and Synthesis.

Cabergoline Powder, commonly referred to as Caber in the community, is a dopamine agonist used to lower prolactin levels in the body. Many athletes use Cabergoline CAS 81409-90-7 to counteract the elevated levels of prolactin found in drugs such as carte blanche and Trenbolone. Cabergoline Raw Materials is an ergot alkaloid derivative that is a dopamine receptor agonist and acts similarly to bromocriptine. It is characterized as potent, long-acting and selective, with a high affinity for D2 dopamine receptors. It also has a strong and persistent inhibitory effect on mammary gland secretion.

Application/Function of Cabergoline Powder.

Cabergoline Powder is mainly used for Parkinson's disease, Parkinson's syndrome and hyperprolactimia. This product can reduce the severity of the "switching phenomenon" caused by long-term administration of levodopa, significantly increase the time of the "on" state, and reduce the need for levodopa by 18%, a long-acting dopamine antagonist. For the treatment of hyperprolactin caused by primary or pituitary tumors. Cabergoline (FCE-21336) is a long-acting dopamine (CAudate) agonist and prolactin inhibitor.

This product is easy to absorb, the peak time of blood concentration is 1 ~ 3 hours, the plasma protein binding rate is 40%, the half-life is 63 ~ 100 hours. This product is widely metabolized by hydrolysis and is excreted mainly in bile and feces.

It is mainly used for Parkinson's disease, Parkinson's syndrome and hyperprolactimia. This product can reduce the severity of the "switching phenomenon" caused by long-term administration of levodopa, significantly increase the time of "on" state, and reduce the need for levodopa by 18%.

• 1. For early and late Parkinson's disease;
• 2. For hyperprolactin disease caused by primary and pituitary tumors;
• 3. Inhibition of physiological lactation and treatment of hyperprolactinemia related diseases.
• Pharmacological effect of Cabergoline Powder
• 1. When combined with levodopa in the treatment of Parkinson's disease, it can enhance the efficacy, so it should be appropriately reduced.
• 2. When combined with macrolides, it can increase blood concentration and show signs of excessive dopamine.
• 3. When used together with antihypertensive drugs, the antihypertensive effect can be strengthened, and the dosage of antihypertensive drugs should be reduced.
• 4, oral hormonal contraceptives can cause amenorrhea or galactorrhea, interference effect, not suitable for use.
• 5. Haloperidol, methyldopa, monoamine oxidase inhibitors, metocloproclopramide, phenothiazines, lipoidel and thiacanthracene can increase the concentration of serum prolactin and interfere with the effect. When combined use is necessary, the dose should be adjusted appropriately.
• 6. When combined with other ergot derivatives, it can cause occasional aggravation of hypertension, but it is rare.
• 7. When combined with alcohol, it may reduce the tolerance to the drug, so it is forbidden to drink alcohol during the medication.
• 8. The combination of butyl benzenes or H2-blockers can increase prolactin concentration and decrease efficacy.